PQ6: Transgenic Mouse Model for Kaposi Sarcoma
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
批准号:
10579826
负责人:
Dirk P Dittmer
金额:
$50.76万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-03-01 至 2025-02-28
关键词:
AIDS related cancerAgeAnimal ModelAnimalsAnniversaryBypassCD4 Lymphocyte CountCell LineCellsCellular StructuresClustered Regularly Interspaced Short Palindromic RepeatsDNA DamageDataDevelopmentDoxorubicinDoxorubicin Hydrochloride LiposomeDrug ModelingsEvaluationFRAP1 geneFrequenciesGanciclovirGene Expression ProfileGenerationsGenesGenetic TranscriptionGenomeHIVHIV SeronegativityHIV/AIDSHemangiosarcomaHumanHuman Herpesvirus 8ImmuneImmunocompetentIn VitroIncidenceKaposi SarcomaKnowledgeLesionLymphomaLyticMalignant NeoplasmsMapsModelingMolecularMolecular TargetMusNeoplasm TransplantationPathogenesisPathway interactionsPersonsPharmaceutical PreparationsPhasePlatelet-Derived Growth FactorProteinsRegimenResearchSafetySignal TransductionStructureStudy modelsTestingTissuesTranscriptTransgenic MiceTransgenic ModelTransplantationTumor-DerivedVaccinesVascular Endothelial Growth FactorsViralViral GenesViral GenomeViral Load resultViral OncogeneVirus Latencyantiretroviral therapycell typecohortcommon treatmentdrug candidatedrug developmentdrug testinghuman fetus tissuein vivoin vivo ModelmTOR Inhibitormouse modelneoplastic cellnovelnovel therapeuticspermissivenesspomalidomidepreventpreventive interventionresponsetargeted treatmenttumortumorigenesisvaccine developmentvaccine evaluation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary Abstract
After 25 years there is still is no adequate animal model for Kaposi Sarcoma (KS), which is the most common
cancer in people living with HIV/AIDS world-wide. Notably, KS develops even in HIV-infected person with
normal CD4 counts and no detectable HIV viral load, as well as in HIV-negative persons – so called classic
KS. The KS-associated herpesvirus (KSHV) is necessary for KS. Rather than focusing on one specific viral
gene, we inserted the entire 138,146 bp KSHV viral genome into transgenic mice. These develop
angiosarcoma and the KSHV genes are expressed in the tumor. This proposal seeks to understand the
mechanism of KS tumorigenesis and to study known and novel drug candidates. This proposal responds to
NCI provocative question six: “Can novel in vitro and in vivo models of HIV/AIDS-associated malignancies be
developed to study their development, pathogenesis, and the potential evaluation of
novel treatments for common HIV/AIDS-associated malignancies?”
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
-
批准号:10334549
-
项目类别:
-
资助金额:$51.54万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
-
批准号:10434864
-
项目类别:
-
资助金额:$18.45万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
-
批准号:10652401
-
项目类别:
-
资助金额:$18.45万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
-
批准号:10084558
-
项目类别:
-
资助金额:$21.23万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
-
批准号:10115683
-
项目类别:
-
资助金额:$52.16万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
-
批准号:10238161
-
项目类别:
-
资助金额:$18.45万
-
财政年份:2020
-
负责人:Dirk P Dittmer
-
依托单位:
Planning for a National Non-Communicable Disease Center of Research Excellence
-
批准号:9337384
-
项目类别:
-
资助金额:$25.18万
-
财政年份:2016
-
负责人:Dirk P Dittmer
-
依托单位:
Planning for a National Non-Communicable Disease Center of Research Excellence
-
批准号:9193832
-
项目类别:
-
资助金额:$26.48万
-
财政年份:2016
-
负责人:Dirk P Dittmer
-
依托单位:
Origin and Lineage of Differentiation of Kaposi's Sarcoma
-
批准号:8839925
-
项目类别:
-
资助金额:$17.29万
-
财政年份:2015
-
负责人:Dirk P Dittmer
-
依托单位:
HIV and substances of abuse influence exosomes and endothelial cell function
-
批准号:9304176
-
项目类别:
-
资助金额:$37.05万
-
财政年份:2015
-
负责人:Dirk P Dittmer
-
依托单位:
Origin and Lineage of Differentiation of Kaposi's Sarcoma
-
批准号:9109595
-
项目类别:
-
资助金额:$17.33万
-
财政年份:2015
-
负责人:Dirk P Dittmer
-
依托单位:
HIV and substances of abuse influence exosomes and endothelial cell function
-
批准号:8987274
-
项目类别:
-
资助金额:$39.2万
-
财政年份:2015
-
负责人:Dirk P Dittmer
-
依托单位:
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
-
批准号:8590757
-
项目类别:
-
资助金额:$16.53万
-
财政年份:2013
-
负责人:Dirk P Dittmer
-
依托单位:
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
-
批准号:8720728
-
项目类别:
-
资助金额:$19.24万
-
财政年份:2013
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis
-
批准号:10380053
-
项目类别:
-
资助金额:$36.93万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis in Oral Epithelia
-
批准号:8064006
-
项目类别:
-
资助金额:$30.51万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis in Oral Epithelia
-
批准号:7835669
-
项目类别:
-
资助金额:$31.45万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis
-
批准号:10609801
-
项目类别:
-
资助金额:$36.93万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis
-
批准号:8734371
-
项目类别:
-
资助金额:$37.78万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
ART Modulation of Viral Pathogenesis in Oral Epithelia
-
批准号:7609198
-
项目类别:
-
资助金额:$31.77万
-
财政年份:2007
-
负责人:Dirk P Dittmer
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: